Breast Cancer
Liquid Biopsy Firm QCDx Closes $7M Financing Round
The proceeds will be used to launch a new diagnostic instrument, a breast cancer monitoring assay, and proprietary multiplex immunofluorescence reagent kits.
The test can be used to better stratify cancer patients and determine the likelihood of breast cancer metastasizing.
Natera Enrolls First Patients in HEROES Metastatic HER2+ Breast Cancer Trial
Natera's Signatera test and diagnostic imaging will be used to monitor patients for progression-free survival over the course of one year.
Precision Medicine Startup Ataraxis AI Nabs $20.4M in Series Financing
Ataraxis AI will use the new funding to bring to market its first offering, Ataraxis Breast, an AI-native prognostic/predictive platform for breast cancer.
The firm's test will be used to aid the detection of cancer in patients with dense breast tissue, which can be more difficult to analyze with mammography alone.